Management of vascular complications following calcium hydroxylapatite filler injections: a systemic review of cases and experimental studies

Abstract

Aim: Dermal fillers are increasingly popular procedures. Inadvertent intraarterial injection of fillers, particularly with calcium hydroxylapatite (CaHA), can result in devastating consequences. A systemic review was performed to summarize management strategies to treat CaHA-associated vascular complications.

Methods: The methodology of this review was derived from The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA). In addition, this paper presents a previously unreported case of a CaHA-associated vascular complication.

Results: There were 32 articles describing 42 cases, plus our case included in this review. There were 15 cases of vision complications, 23 cases of non-vision complications, and 5 experimental studies. The most common injection sites reported were nasal region for vision complications (45%) and nasolabial folds for non-vision complications (40%). Of the 38 human cases, the most prevalent treatment choice was steroids (24 cases, 63%). Complete or near complete improvement was reported in 83% of non-vision complications and 40% of vision complications. There was no noticeable homogeneity in the management strategies and outcomes of the patients. Of the 5 experimental studies, no clear consensus on treatments was found.

Conclusion: Vascular complications of CaHA are seemingly uncommon, but it is widely suspected that this is due to underreporting. While best management is prevention, preparation for a potential complication is equally important. Derived from CaHA literature, hyaluronic acid filler complication protocols, findings of this review, and personal experiences, this report proposes management strategies for CaHA-associated vascular complications. We hope these strategies provide a much-needed framework for injectors to refer to and utilize as needed.

Keywords

Filler-associated intravascular complications / filler-associated blindness / vascular occlusion management / calcium hydroxylapatite / Radiesse

References

[1] Chatrath V,Goodman GJ.Soft-tissue filler-associated blindness: a systematic review of case reports and case series.Plast Reconstr Surg Glob Open2019;7:e2173 PMCID:PMC6554164

[2] Liu YC,Chen YF.Near complete recovery of visual acuity after calcium hydroxylapatite injection-related vision loss: a case report and literature review.Ann Plast Surg2020;84:S123-7

[3] Master M.Hyaluronic acid filler longevity and localization: magnetic resonance imaging evidence.Plast Reconstr Surg2021;147:50e-3e

[4] RADIESSE^®. Mechanism of Action. Meamy Aesthetics 2021. Available from: https://radiesse.com/hcp/professionals/about-radiesse/how-radiesse-works/ [Last accessed on 26 Aug 2022]

[5] RADIESSE^®. Injectable implant instructions for use. Franksville, WI: Merz North America Inc.; 2016. Available from: https://radiesse.com/app/uploads/EM00543-04.pdf. [Last accessed on 26 Aug 2022]

[6] Jacovella PF.Use of calcium hydroxylapatite (Radiesse) for facial augmentation.Clin Interv Aging2008;3:161-74 PMCID:PMC2544361

[7] Ahn MS.Calcium hydroxylapatite: radiesse.Facial Plast Surg Clin North Am2007;15:85-90

[8] King M,Convery C.Management of a vascular occlusion associated with cosmetic injections.J Clin Aesthet Dermatol2020;13:E53-8 PMCID:PMC7028373

[9] Rauso R,Fragola R,Nicoletti GF.Skin necrosis and vision loss or impairment after facial filler injection.J Craniofac Surg2020;31:2289-93

[10] Page MJ,Bossuyt PM.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.BMJ2021;372:n71 PMCID:PMC8005924

[11] Sung MS,Woo KI.Ocular ischemia and ischemic oculomotor nerve palsy after vascular embolization of injectable calcium hydroxylapatite filler.Ophthalmic Plast Reconstr Surg2010;26:289-91

[12] Czyz C.Injection filler, vascular occlusion, and tissue necrosis.Otolaryngol Head Neck Surg2011;145:P139-P139

[13] Kim YJ.Bilateral blindness after filler injection.Plast Reconstr Surg2013;131:298e-9e

[14] Chang TY,Huang YH.Blindness after calcium hydroxylapatite injection at nose.J Plast Reconstr Aesthet Surg2014;67:1755-7

[15] Hsiao SF.Partial vision recovery after iatrogenic retinal artery occlusion.BMC Ophthalmol2014;14:120 PMCID:PMC4197310

[16] Chou CC,Tsai YY,Lin HJ.Choroid vascular occlusion and ischemic optic neuropathy after facial calcium hydroxyapatite injection - a case report.BMC Surg2015;15:21 PMCID:PMC4359764

[17] Hsieh YH,Huang JS.Severe ocular complications following facial calcium hydroxylapatite injections: two case reports.Taiwan J Ophthalmol2015;5:36-9. PMCID:PMC5602722

[18] Cohen E,Leibovitch I.A case report of ophthalmic artery emboli secondary to Calcium Hydroxylapatite filler injection for nose augmentation - long-term outcome.BMC Ophthalmol2016;16:98 PMCID:PMC4938948

[19] Glass LR, Choi CJ, Lee NG. Orbital complication following calcium hydroxylapatite filler injection.Ophthalmic Plast Reconstr Surg2017;33:S16-7

[20] Marumo Y,Hashimoto M.Visual impairment by multiple vascular embolization with hydroxyapatite particles.Orbit2018;37:165-70

[21] Sung WI,Chen LJ.Ocular complications following cosmetic filler injection.JAMA Ophthalmol2018;136:e180716

[22] Vu PQ,Tao JP.Light perception vision recovery after treatment for calcium hydroxylapatite cosmetic filler-induced blindness.Ophthalmic Plast Reconstr Surg2018;34:e189-92

[23] Oh DJ,Mieler WF.Ophthalmic artery occlusion and subsequent retinal fibrosis from a calcium hydroxylapatite filler injection.J Vitreoretin Dis2019;3:190-3 PMCID:PMC6533913

[24] Georgescu D,McCann JD.Skin necrosis after calcium hydroxylapatite injection into the glabellar and nasolabial folds.Ophthalmic Plast Reconstr Surg2009;25:498-9

[25] Winslow CP.The management of dermal filler complications.Facial Plast Surg2009;25:124-8

[26] Dayan SH,Mathison CC.Management of impending necrosis associated with soft tissue filler injections.J Drugs Dermatol2011;10:1007-12

[27] Beer K,Beer J.A treatment protocol for vascular occlusion from particulate soft tissue augmentation.J Clin Aesthet Dermatol2012;5:44-7 PMCID:PMC3366448

[28] Darling MD,Fabi SG.Impending necrosis after injection of hyaluronic acid and calcium hydroxylapatite fillers: report of 2 cases treated with hyperbaric oxygen therapy.Dermatol Surg2014;40:1049-52

[29] Tracy L,Nelson JS,Wong B.Calcium hydroxylapatite associated soft tissue necrosis: a case report and treatment guideline.J Plast Reconstr Aesthet Surg2014;67:564-8

[30] Schuster B.Injection rhinoplasty with hyaluronic acid and calcium hydroxyapatite: a retrospective survey investigating outcome and complication rates.Facial Plast Surg2015;31:301-7

[31] Dominguez S,Dobke M.Treatment protocol for acute arterial occlusion secondary to facial revolumization procedures.Emerg Med2017;49:221-9

[32] Rocha ACNA & Hirano CF.Extravascular occlusion with calcium hydroxyapatite filler efficiently treated with hyaluronidase. Poster presented at: 24th World Congress of Dermatology; 2019. doi:10.13140/RG.2.2.29506.73923.

[33] Uittenbogaard D,Bauland CG.Hyperbaric oxygen therapy for dermal ischemia after dermal filler injection with calcium hydroxylapatite: a case report.Undersea Hyperb Med2019;46:207-10

[34] Schelke L,Kadouch J.Incidence of vascular obstruction after filler injections.Aesthet Surg J2020;40:NP457-60 PMCID:PMC7357869

[35] van Loghem J,Pavicic T.Managing intravascular complications following treatment with calcium hydroxylapatite: an expert consensus.J Cosmet Dermatol2020;19:2845-58 PMCID:PMC7687073

[36] Williams MN.Management of calcium hydroxyapatite vascular occlusion in a hemophiliac with HIV-associated facial lipoatrophy.Dermatol Surg2021;47:1173-4

[37] Hwang CJ,Pimentel A,Goldberg RA.Rethinking the role of nitroglycerin ointment in ischemic vascular filler complications: an animal model with ICG imaging.Ophthalmic Plast Reconstr Surg2016;32:118-22

[38] thiosulfate injection dissolves calcium hydroxylapatite particles: an animal study.J Am Acad Dermatol2018;79:AB265

[39] Robinson DM.In vitro analysis of the degradation of calcium hydroxylapatite dermal filler: a proof-of-concept study.Dermatol Surg2018;44 Suppl 1:S5-9

[40] Danysz W,Hengl T.Can sodium thiosulfate act as a reversal agent for calcium hydroxylapatite filler?.Clin Cosmet Investig Dermatol2020;13:1059-73 PMCID:PMC7781022

[41] Yankova M,Frank K.Intraarterial degradation of calcium hydroxylapatite using sodium thiosulfate - an in vitro and cadaveric study.Aesthet Surg J2021;41:NP226-36

[42] DeLorenzi C.Complications of injectable fillers, part 2: vascular complications.Aesthet Surg J2014;34:584-600

[43] Sclafani AP.Treatment of injectable soft tissue filler complications.Dermatol Surg2009;35 Suppl 2:1672-80

[44] Lazzeri D,Figus M,Pantaloni M.Blindness following cosmetic injections of the face.Plast Reconstr Surg2012;129:995-1012

[45] Carruthers JDA.Commentary on: a guide to doppler ultrasound analysis of the face in cosmetic medicine.Aesthet Surg J2021;41:NP1645-6

[46] Velthuis PJ,Schelke LW.A guide to doppler ultrasound analysis of the face in cosmetic medicine. part 2: vascular mapping.Aesthet Surg J2021;41:NP1633-44

[47] Loghem JAJ, Humzah D, Kerscher M. Cannula versus sharp needle for placement of soft tissue fillers: an observational cadaver study.Aesthet Surg J2017;38:73-88

[48] Yeh LC,Welsh K.Arterial penetration with blunt-tipped cannulas using injectables: a false sense of safety?.Dermatol Surg2017;43:464-7

[49] Pavicic T,Frank K,Tamura B.Arterial wall penetration forces in needles versus cannulas.Plast Reconstr Surg2019;143:504e-12e

[50] Kim J.Novel forehead augmentation strategy: forehead depression categorization and calcium-hydroxyapatite filler delivery after tumescent injection.Plast Reconstr Surg Glob Open2018;6:e1858 PMCID:PMC6191212

[51] Casabona G.Blood aspiration test for cosmetic fillers to prevent accidental intravascular injection in the face.Dermatol Surg2015;41:841-7

[52] Loghem JA, Fouché JJ, Thuis J. Sensitivity of aspiration as a safety test before injection of soft tissue fillers.J Cosmet Dermatol2018;17:39-46

[53] Cugati S,Chen CS.Treatment options for central retinal artery occlusion.Curr Treat Options Neurol2013;15:63-77 PMCID:PMC3553407

[54] Seethapathy H,Sinha S,Nigwekar SU.Review: update on the management of calciphylaxis.QJM2019;112:29-34

[55] Kirby JP,Schuerer DJE,Bochicchio GV.Essentials of hyperbaric oxygen therapy: 2019 review.Mo Med2019;116:176-9. PMCID:PMC6690283

[56] Dhaliwal A. PDE5 inhibitors. [Updated 2021 Jun 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK549843/ [Last accessed on 26 Aug 2022]

[57] Hew MR. Prostaglandin E1. [Updated 2021 Apr 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546629/?report=classic [Last accessed on 26 Aug 2022]

[58] Khan KM,Schaefer TJ. Nifedipine. [Updated 2021 Aug 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK537052/ [Last accessed on 26 Aug 2022]

[59] Rumelt S,Rehany U.Aggressive systematic treatment for central retinal artery occlusion.Am J Ophthalmol1999;128:733-8

[60] Mac Grory B,Biousse V.Management of central retinal artery occlusion: a scientific statement from the american heart association.Stroke2021;52:e282-94

[61] Prado G.Ocular pain and impending blindness during facial cosmetic injections: is your office prepared?.Aesthetic Plast Surg2017;41:199-203

[62] Feltgen N,Jurklies B.Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1: EAGLE study report no. 1.Graefes Arch Clin Exp Ophthalmol2006;244:950-6

[63] Sansone CM,Giordano G,Destrebecq A.Relationship between capillary refill time at triage and abnormal clinical condition: a prospective study.Open Nurs J2017;11:84-90 PMCID:PMC5543682